COMP <GO>
KZIA vs MENS // EV/EBITDA & P/E VALUATION
Kazia Therapeutics Limited (NASDAQ) VS. Jyong Biotech Ltd. (NASDAQ) • 15-METRIC TALLY: KZIA 0
— MENS 2
■ METRIC PARITY
LAST: $8.50 (-2.52%) • MKT CAP: $135.6M
valuation
—
LAST: $1.88 (0.00%) • MKT CAP: $142.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KZIA VS. MENS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KZIA | MENS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -28.80% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -2.13% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 1/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.0 | 47.2 | -1.17 | MENS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $135.6M | $142.9M | -$7.3M | MENS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KZIA REV | MENS REV | KZIA GROSS % | MENS GROSS % | KZIA FCF | MENS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $0 | — | — | — | -$3.0M |
| FY 2024 | — | $0 | — | — | — | -$3.6M |
| FY 2023 | — | $0 | — | — | — | -$2.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KZIA // BETA —
MENS // BETA —